Literature DB >> 6284395

High-dose cyclophosphamide with autologous marrow transplantation as initial treatment of small cell carcinoma of the bronchus.

R L Souhami, P G Harper, D Linch, C Trask, A H Goldstone, J Tobias, S G Spiro, D M Geddes, J D Richards.   

Abstract

Sixteen patients with untreated small cell carcinoma of the bronchus received cyclophosphamide in a total dose of 160-200 mg/kg. Autologous marrow transplantation was used to minimise the period of hypoplasia and 2-mercaptoethane sulphonate to prevent urothelial toxicity. The procedure was well tolerated, with predictable and manageable toxicity. Complete radiological and bronchoscopic response was achieved in seven patients and partial response in a further seven. High-dose cyclophosphamide may be a useful initial treatment for this disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284395     DOI: 10.1007/bf00292868

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  8 in total

Review 1.  Staging procedures and prognostic features in small cell anaplastic bronchogenic carcinoma.

Authors:  H H Hansen; P Dombernowsky; F R Hirsch
Journal:  Semin Oncol       Date:  1978-09       Impact factor: 4.929

Review 2.  Treatment of bronchogenic carcinoma. II. Small cell.

Authors:  L E Broder; M H Cohen; O S Selawry
Journal:  Cancer Treat Rev       Date:  1977-12       Impact factor: 12.111

3.  Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma.

Authors:  C D Buckner; R Briggs; R A Clift; A Fefer; D D Funk; H Glucksberg; P E Neiman; R Storb; E D Thomas
Journal:  Cancer Chemother Rep       Date:  1974 Sep-Oct

4.  High dose combination chemotherapy (TACC) with and without autologous bone marrow transplantation for the treatment of acute leukaemia and other malignant diseases: kinetics of recovery of haemopoiesis. A preliminary study of 12 cases.

Authors:  N C Gorin; A Najman; C Salmon; J Y Muller; J C Petit; R David; J Stachowiak; F H Marie; Y Parlier; G Duhamel
Journal:  Eur J Cancer       Date:  1979-09       Impact factor: 9.162

Review 5.  Small-cell lung cancer. A curable disease.

Authors:  R K Oldham; F A Greco
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.

Authors:  W Scheef; H O Klein; N Brock; H Burkert; U Günther; H Hoefer-Janker; D Mitrenga; J Schnitker; R Voigtmann
Journal:  Cancer Treat Rep       Date:  1979-03

7.  High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors.

Authors:  G Spitzer; K A Dicke; J Litam; D S Verma; A Zander; V Lanzotti; M Valdivieso; K B McCredie; M L Samuels
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

8.  Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.

Authors:  T J McElwain; D W Hedley; G Burton; H M Clink; M Y Gordon; M Jarman; C A Juttner; J L Millar; R A Milsted; G Prentice; I E Smith; D Spence; M Woods
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640

  8 in total
  10 in total

1.  Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer.

Authors:  R L Souhami; H T Hajichristou; D W Miles; H M Earl; P G Harper; C M Ash; A H Goldstone; S G Spiro; D M Geddes; J S Tobias
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Lung cancer--areas of progress.

Authors:  S G Spiro
Journal:  Postgrad Med J       Date:  1984-03       Impact factor: 2.401

3.  High-dose cyclophosphamide with autologous marrow transplantation for small cell carcinoma of the bronchus.

Authors:  R L Souhami; P G Harper; D Linch; C Trask; A H Goldstone; J S Tobias; S G Spiro; D M Geddes; J D Richards
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung.

Authors:  M Mabry; J A Speak; J D Griffin; R A Stahel; S D Bernal
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

5.  High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma.

Authors:  I E Smith; B D Evans; S J Harland; B A Robinson; J R Yarnold; J G Glees; H T Ford
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 6.  High dose chemotherapy with autologous marrow rescue in the treatment of resistant solid tumors.

Authors:  C F LeMaistre; W A Knight
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

Review 7.  Intensive chemotherapy for solid tumours--current clinical applications.

Authors:  S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Decreased plasma half-life of cyclophosphamide during repeated high-dose administration.

Authors:  M I Graham; I C Shaw; R L Souhami; B Sidau; P G Harper; A E McLean
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung.

Authors:  D Cunningham; S W Banham; A H Hutcheon; A Dorward; S Ahmedzai; P Tansey; M Soukop; R D Stevenson; B R Stack; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Response of a multidrug-resistant human small-cell lung cancer xenograft to chemotherapy.

Authors:  F Arvelo; M F Poupon; A F Goguel; G Lizard; Y Bourgeois; R Arriagada; T Le Chevalier
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.